Gilead Sciences, a Bay Area-headquartered biotech and pharmaceutical company, is laying off 104 workers in Foster City, with ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase ...

Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

Gilead’s layoffs include 72 employees at its Seattle location, which will close. Kite will shut down its Philadelphia ...

The company behind the COVID-19 treatment drug remdesivir and the HIV antiretroviral medication Biktarvy is closing its ...

New outcomes from two datasets derived from the Bictegravir Single Tablet Regimen (BICSTaR) study are consistent with the results observed from multiple Phase 3 clinical trials, which demonstrated the ...

Data shows Latino and Black people make up nearly 30% of the Bay Area population but only about 10% of active medical ...

Fintel reports that on November 14, 2024, Citigroup initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Buy ...

January, come a year after the drugmaker slashed 7 percent of the workforce at Kite Pharma, its cell therapy business.

Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company's website at www.gilead.com, follow ...

went public with a $330 million pre-money valuation and was acquired by Gilead (Foster City, CA, USA) for $2.3 billion in 2006; Alnylam (Cambridge, MA, USA) has grown from $100 million pre-money ...